These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16523360)

  • 1. Predictors of regional nodal disease in patients with thin melanomas.
    Karakousis GC; Gimotty PA; Botbyl JD; Kesmodel SB; Elder DE; Elenitsas R; Ming ME; Guerry D; Fraker DL; Czerniecki BJ; Spitz FR
    Ann Surg Oncol; 2006 Apr; 13(4):533-41. PubMed ID: 16523360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.
    Kesmodel SB; Karakousis GC; Botbyl JD; Canter RJ; Lewis RT; Wahl PM; Terhune KP; Alavi A; Elder DE; Ming ME; Guerry D; Gimotty PA; Fraker DL; Czerniecki BJ; Spitz FR
    Ann Surg Oncol; 2005 Jun; 12(6):449-58. PubMed ID: 15864482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients.
    Karakousis GC; Gimotty PA; Czerniecki BJ; Elder DE; Elenitsas R; Ming ME; Fraker DL; Guerry D; Spitz FR
    Ann Surg Oncol; 2007 May; 14(5):1596-603. PubMed ID: 17285396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
    Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    MandalĂ  M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
    Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
    Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; BĂ©atrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse.
    Govindarajan A; Ghazarian DM; McCready DR; Leong WL
    Ann Surg Oncol; 2007 Feb; 14(2):906-12. PubMed ID: 17136471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node status in melanoma: a valuable prognostic factor?
    Topar G; Eisendle K; Zelger B; Fritsch P
    Br J Dermatol; 2006 Jun; 154(6):1080-7. PubMed ID: 16704637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of sentinel lymph node biopsy in patients with thin melanoma.
    Wong SL; Brady MS; Busam KJ; Coit DG
    Ann Surg Oncol; 2006 Mar; 13(3):302-9. PubMed ID: 16485151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.
    Zogakis TG; Essner R; Wang HJ; Foshag LJ; Morton DL
    Ann Surg Oncol; 2007 May; 14(5):1604-11. PubMed ID: 17333418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled study.
    Sartore L; Papanikolaou GE; Biancari F; Mazzoleni F
    Int J Surg; 2008 Jun; 6(3):205-9. PubMed ID: 18417434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients.
    Socrier Y; Lauwers-Cances V; Lamant L; Garrido I; Lauwers F; Lopez R; Rochaix P; Chevreau C; Payoux P; Viraben R; Paul C; Meyer N
    Br J Dermatol; 2010 Apr; 162(4):830-4. PubMed ID: 20030641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The correlation of regression in primary melanoma with sentinel lymph node status.
    Kaur C; Thomas RJ; Desai N; Green MA; Lovell D; Powell BW; Cook MG
    J Clin Pathol; 2008 Mar; 61(3):297-300. PubMed ID: 17675538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumour regression is not predictive for higher risk of sentinel node involvement in thin melanomas (Breslow thickness < or = 1 mm)].
    Kramkimel N; Maubec E; Boitier F; Cavalcanti A; Beldi M; Mamelle G; Kolb F; Duvillard P; Avril MF
    Ann Dermatol Venereol; 2010 Apr; 137(4):276-80. PubMed ID: 20417360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas.
    Cecchi R; Pavesi M; Buralli L; Innocenti S; De Gaudio C
    Chir Ital; 2008; 60(2):257-60. PubMed ID: 18689175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.